Although carriers of LoF APOB variants exhibited a substantially reduced risk of atherosclerotic events, this benefit was outweighed by a significant long‐term increase in the risk of CLD, amplified in individuals with obesity or diabetes. This evidence concerns the gene APOB and obesity due to melanocortin 4 receptor deficiency.